Home Other Building Blocks 2-((4-(2-(3-Cyclohexyl-1-(4-cyclohexylbutyl)ureido)ethyl)phenyl)thio)-2-methylpropanoic acid

2-((4-(2-(3-Cyclohexyl-1-(4-cyclohexylbutyl)ureido)ethyl)phenyl)thio)-2-methylpropanoic acid

CAS No.:
265129-71-3
Catalog Number:
AG002TIU
Molecular Formula:
C29H46N2O3S
Molecular Weight:
502.7521
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%
1 week
United States
$223
- +
10mg
98%
1 week
United States
$307
- +
25mg
98%
1 week
United States
$490
- +
50mg
98%
1 week
United States
$807
- +
100mg
98%
1 week
United States
$1140
- +
Product Description
Catalog Number:
AG002TIU
Chemical Name:
2-((4-(2-(3-Cyclohexyl-1-(4-cyclohexylbutyl)ureido)ethyl)phenyl)thio)-2-methylpropanoic acid
CAS Number:
265129-71-3
Molecular Formula:
C29H46N2O3S
Molecular Weight:
502.7521
MDL Number:
MFCD06798379
IUPAC Name:
2-[4-[2-[4-cyclohexylbutyl(cyclohexylcarbamoyl)amino]ethyl]phenyl]sulfanyl-2-methylpropanoic acid
InChI:
InChI=1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)
InChI Key:
PKNYXWMTHFMHKD-UHFFFAOYSA-N
SMILES:
O=C(N(CCc1ccc(cc1)SC(C(=O)O)(C)C)CCCCC1CCCCC1)NC1CCCCC1
Properties
Complexity:
636  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
502.323g/mol
Formal Charge:
0
Heavy Atom Count:
35  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
502.758g/mol
Monoisotopic Mass:
502.323g/mol
Rotatable Bond Count:
12  
Topological Polar Surface Area:
94.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
8  
Literature
Title Journal
The urinary metabolites of DINCH(®) have an impact on the activities of the human nuclear receptors ERα, ERβ, AR, PPARα and PPARγ. Toxicology letters 20180501
Agonistic and antagonistic effects of phthalates and their urinary metabolites on the steroid hormone receptors ERα, ERβ, and AR. Toxicology letters 20170805
Hepatic Aryl Hydrocarbon Receptor Attenuates Fibroblast Growth Factor 21 Expression. The Journal of biological chemistry 20160715
Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PloS one 20140101
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 20130801
In vitro toxicological characterization of perfluorinated carboxylic acids with different carbon chain lengths. Toxicology letters 20130412
Long-term stability of primary rat hepatocytes in micropatterned cocultures. Journal of biochemical and molecular toxicology 20130301
Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ. American journal of physiology. Regulatory, integrative and comparative physiology 20130101
Induction of the fatty acid 2-hydroxylase (FA2H) gene by Δ(9)-tetrahydrocannabinol in human breast cancer cells. The Journal of toxicological sciences 20130101
Rodent thyroid, liver, and fetal testis toxicity of the monoester metabolite of bis-(2-ethylhexyl) tetrabromophthalate (tbph), a novel brominated flame retardant present in indoor dust. Environmental health perspectives 20121201
Roles of α-linolenic acid on IGF-I secretion and GH/IGF system gene expression in porcine primary hepatocytes. Molecular biology reports 20121201
Synthesis, radiolabeling and initial in vivo evaluation of [(11)C]KSM-01 for imaging PPAR-α receptors. Bioorganic & medicinal chemistry letters 20121001
Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. Journal of medicinal chemistry 20120614
Transcription of genes involved in fat metabolism in chicken embryos exposed to the peroxisome proliferator-activated receptor alpha (PPARα) agonist GW7647 or to perfluorooctane sulfonate (PFOS) or perfluorooctanoic acid (PFOA). Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20120601
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ. PloS one 20120101
Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chemistry & biology 20111123
Effect of synthetic ligands of PPAR α, β/δ, γ, RAR, RXR and LXR on the fatty acid composition of phospholipids in mice. Lipids 20111101
Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism. European journal of medicinal chemistry 20111001
Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro. Journal of natural products 20110826
Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists. Bioorganic & medicinal chemistry letters 20110815
Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arteriosclerosis, thrombosis, and vascular biology 20110601
Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. Journal of lipid research 20110501
Activation of peroxisome proliferator-activated receptor-α enhances fatty acid oxidation in human adipocytes. Biochemical and biophysical research communications 20110422
Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents. Journal of medicinal chemistry 20110210
Molecular mechanisms underlying the inhibition of IFN-γ-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. Journal of cellular biochemistry 20110201
PPAR activation has dichotomous control on the expression levels of cytosolic and secretory phospholipase A2 in astrocytes; inhibition in naïve, untreated cells and enhancement in LPS-stimulated cells. Journal of neurochemistry 20101001
Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Molecular pharmacology 20100901
Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase. The Journal of nutritional biochemistry 20100701
Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator. Bioorganic & medicinal chemistry letters 20100415
Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain. Protein expression and purification 20100401
Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chemical research in toxicology 20100315
Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes. Endocrinology 20100101
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proceedings of the National Academy of Sciences of the United States of America 20091208
Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists. Journal of medicinal chemistry 20091022
Synergistic acceleration of thyroid hormone degradation by phenobarbital and the PPAR alpha agonist WY14643 in rat hepatocytes. Toxicology and applied pharmacology 20091001
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nature chemical biology 20091001
Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels. Molecular pharmacology 20090801
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. European journal of pharmacology 20090624
Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine. European journal of gastroenterology & hepatology 20090601
Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. Endocrinology 20090401
Rapid non-genomic regulation of Ca2+ signals and insulin secretion by PPAR alpha ligands in mouse pancreatic islets of Langerhans. The Journal of endocrinology 20090201
Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARalpha in human macrophages. Journal of molecular biology 20081219
PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free radical biology & medicine 20081215
Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. Bioorganic & medicinal chemistry 20081201
15-deoxy-delta 12,14-prostaglandin J(2) inhibits the synthesis of the acute phase protein SIP24 in cartilage: Involvement of COX-2 in resolution of inflammation. Journal of cellular physiology 20081101
Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. Journal of medicinal chemistry 20080828
Effects of the mango components mangiferin and quercetin and the putative mangiferin metabolite norathyriol on the transactivation of peroxisome proliferator-activated receptor isoforms. Journal of agricultural and food chemistry 20080514
PPARalpha and PPARbeta are differentially affected by ethanol and the ethanol metabolite acetaldehyde in the MCF-7 breast cancer cell line. Toxicological sciences : an official journal of the Society of Toxicology 20080301
SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail. Bioorganic & medicinal chemistry letters 20080201
Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism. Stem cells (Dayton, Ohio) 20080101
PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. British journal of pharmacology 20071201
Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons. Journal of neurochemistry 20071101
Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 20070918
Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. European journal of pharmacology 20070702
Identification of apolipoprotein A-I as a 'STOP' signal for myopia. Molecular & cellular proteomics : MCP 20061101
A facile one-pot preparation of alkyl aminoaryl sulfides for the synthesis of GW7647 as an agonist of peroxisome proliferator-activated receptor alpha. The Journal of organic chemistry 20060721
Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. Toxicology letters 20060601
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Analytical biochemistry 20050901
Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. The Journal of pharmacology and experimental therapeutics 20050701
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 20050601
Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells. The FEBS journal 20050601
Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. The Journal of clinical endocrinology and metabolism 20050301
Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy. Molecular genetics and metabolism 20031201
Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 20031111
Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. Journal of immunology (Baltimore, Md. : 1950) 20030701
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. The Journal of biological chemistry 20020419
Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 20020401
Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorganic & medicinal chemistry letters 20010507
A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 19990701
Properties